CStone Pharmaceuticals (SEHK:2616) Valuation After FDA Clearance For Phase II Immunotherapy Trial

FDA clearance puts CS2009 in focus for CStone investors

CStone Pharmaceuticals (SEHK:2616) said the U.S. FDA has cleared its IND for a Phase II trial of immunotherapy candidate CS2009 in advanced solid tumors, expanding an ongoing global multicenter study.

See our latest analysis for CStone Pharmaceuticals.

The FDA clearance comes as CStone’s share price sits at HK$5.91, with a 7 day share price return of 14.98% and a 1 year total shareholder return of 113.36%. This suggests momentum has strengthened recently, even though longer term total shareholder returns over 3 and 5 years have been mixed.

If this kind of clinical progress has your attention, it could be a good moment to see what other healthcare opportunities our 106 healthcare AI stocks might surface for you.

With CStone trading at HK$5.91 against an average analyst price target of HK$13.96 and an estimated intrinsic value gap, the key question is whether this signals mispricing or if the market already reflects its future growth potential.

Preferred Price-to-Sales of 38x: Is it justified?

On the surface, CStone looks inexpensive against some valuation models, yet its P/S ratio of 38x at a share price of HK$5.91 tells a different story.

P/S compares the company’s market value to its revenue, so a 38x multiple means investors are currently paying HK$38 for every HK$1 of sales. For a business that is still loss making, that is a punchy starting point that leans heavily on expectations for future revenue and profit.

Here, the contrast is sharp. CStone is described as trading at 83.1% below one estimate of fair value, and the SWS DCF model indicates the shares at HK$5.91 sit well below an estimated future cash flow value of HK$34.97 per share. At the same time, that 38x P/S is labelled expensive compared to a fair P/S level of 4.4x and is also above both the Hong Kong Biotechs industry average of 14.2x and a peer average of 25.4x, implying the market is already assigning a premium to its revenue base.

Compared with those benchmarks, the current P/S suggests investors are accepting a much richer revenue multiple than both the industry and the fair ratio indicate. The DCF output also points to a very wide gap that the share price would need to close if those cash flow assumptions are met over time.

Explore the SWS fair ratio for CStone Pharmaceuticals

Result: Price-to-Sales of 38x (OVERVALUED)

However, you also need to weigh clinical or regulatory setbacks for CS2009, as well as the current net loss of CN¥377.089m, as potential pressure points for sentiment.

Find out about the key risks to this CStone Pharmaceuticals narrative.

Another view: DCF points in the opposite direction

While the 38x P/S ratio flags CStone as expensive next to a 4.4x fair ratio, the SWS DCF model presents a different perspective, with an estimated future cash flow value of HK$34.97 per share versus the current HK$5.91. That is a wide gap, so which signal do you trust more?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CStone Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 224 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own CStone Pharmaceuticals Narrative

If you see the numbers differently or simply want to test your own view, it only takes a few minutes to build a bespoke thesis: Do it your way

A great starting point for your CStone Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If CStone has sharpened your focus, do not stop here. Use these screeners to quickly surface other ideas that match the kind of portfolio you want.

• Spot opportunities others may overlook by checking our screener containing 575 high quality undiscovered gems backed by strong fundamentals and cleaner financial profiles.
• Strengthen the core of your portfolio with companies in the solid balance sheet and fundamentals stocks screener (370 results) that pair financial resilience with consistent fundamentals.
• Reduce portfolio stress by focusing on companies highlighted in our 325 resilient stocks with low risk scores that aim to keep risk in check while you stay invested.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com